secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2022-10-05T23:59:59+00:00
Accession:  0000950170-22-019311
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Bio CEO John McHutchison to retire Dec 31; Jason Okazaki to succeed as CEO Jan 1, 2023
--------------------------------------------------------------------------------

- John G. McHutchison to retire as CEO effective Dec 31, 2022; remains board member and chair of Science & Technology Committee.
- Jason A. Okazaki, current President and COO, appointed President and CEO and board member effective Jan 1, 2023.
- Okazaki joined Assembly Bio in 2020; previously SVP Legal at Gilead; promoted to COO in 2021 and President in 2022.
- Dr. McHutchison led expansion beyond core HBV inhibitors to HDV entry inhibitor, interferon-α receptor agonist, and herpes programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022019311/0000950170-22-019311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022019311/asmb-20221005.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer